drugset / Trial / NCT00519649

Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.

NCT00519649 ↗

Phase 4 Completed 301 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the persistence of immunity to hepatitis B in children who received three consecutive doses of HBV vaccine (EngerixTM-B) in infancy. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2007-08-31
Primary completion
2007-12-31
Completion
2007-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix™-B Kinder Vaccine — Intramuscular